Press Release

PRINCETON JUNCTION, NJ, November 19, 2007

Highlighted by the introduction of the IQQA® Enterprise Engine technology, EDDA is now reaching the broad radiology imaging market with its universal enterprise solution, which enables fast delivery and easy access of 2D/3D/4D advanced clinical applications on existing PACS workstations in virtually any hospital PACS environment without code-level integration. Available on the IQQA® Enterprise Engine are IQQA®-Chest for digital X-Ray lung nodule CAD, and IQQA®-Liver for contrast MDCT. The IQQA® Enterprise Engine is also capable of accommodating third party imaging applications.

IQQA®-Chest is the only FDA cleared system to offer real-time interactive diagnostic analysis of digital chest X-rays using a comprehensive set of tools to support physicians in their identification, confirmation and quantification of lung nodules. By offering a solution powered by intelligent tools with real-time interaction, the system seamlessly integrates advanced diagnostic analysis technologies into physicians’ softcopy reading process for improved workflow and clinical decision making. Published clinical studies have suggested that IQQA®-Chest may help physicians’ identification of small lesions and reduce inter-observer variation. With the number of chest X-rays that are read on a daily basis worldwide, the immediacy provided by IQQA®-Chest Enterprise allows for expanded use of chest CAD tools on a routine basis, with the prospect of enhancing diagnostic quality on a broad scale.

IQQA®-Liver Enterprise addresses the clinical challenge faced by physicians in efficiently dealing with tremendous data volume from contrast MDCT images of the liver. Combining advanced image analysis algorithms and powerful visualization tools, the software supports physicians to quickly and effectively distill critical diagnostic information from data volume of extraordinary size. It performs automatic anatomy-based phase registration to allow simultaneous visualization and easy cross-referencing of lesion location and characteristics across different phases. IQQA®-Liver Enterprise further provides 3D segmentation and measurement tools for visualization and analysis of liver, liver lesions, and vascular structures. This volumetric analysis not only provides physicians with a powerful visualization aid, but also offers quantification tools to support their clinical decision making and patient care management.

The enabling IQQA® Enterprise Engine (IQQA®-EE) technology is a direct response to the critical challenge that physicians and hospital IT now face in integrating more and more advanced clinical applications into existing PACS workflow. Access to such applications via dedicated stand- alone workstations is no longer accepted as an option in an already stressed workflow. Although static image results could often be sent from these stand-alone workstations back to a primary PACS workstation for review, it is still not possible to enjoy access to the full interactive functionality of these advanced applications at the PACS viewing station.

The IQQA® Enterprise Engine aims to redefine how advanced clinical application can be accessed by physicians and managed by hospital IT. Physicians can now enjoy immediate access to the full real-time 2D/3D/4D functionality of advanced clinical applications at existing
PACS viewing stations. In addition, since the solution does not require code level integration with existing hospital PACS environment, application installation is completed quickly by simply setting up network communication. Possible additional maintenance resources of having to keep up with periodic PACS software upgrade are also saved.

“EDDA is committed to innovation in delivering diagnostic aid solutions. Not only do we develop advanced clinical applications to help improve the early detection, early diagnosis and precise treatment of lethal diseases, but also we see the tremendous importance of the innovative delivery mechanism to enable broad access to such applications”, says Dr. Jian-Zhong Qian, President and CEO of EDDA Technology. “From the success of development of IQQA®-Chest Enterprise to IQQA®-Liver Enterprise, the IQQA® Enterprise Engine demonstrates a new economic way to integrate 2D/3D/4D applications with virtually any existing hospital PACS systems without code level integration. Considering the trend of emerging advanced clinical applications for diagnostic decision aid, the impact of such accessibility enabling technology to deliver diagnostic aid on a broad scale will be significant.”

The IQQA® Enterprise Engine has been successfully demonstrated to run in numerous PACS environments including AGFA, Dynamic Imaging, GE, Kodak, McKesson, Philips, Siemens, etc.

EDDA Technology will be exhibiting the IQQA® Family of Clinical Applications and Platforms in Booth #6534 in the North Hall of McCormick Place at the 93rd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 25 – 30, 2007.

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton Junction, New Jersey, and has a subsidiary in Shanghai, China. IQQA is a registered trademark of EDDA Technology.

For further information, please log on to www.edda-tech.com, or call 609-936-8282.

EDDA IQQA-Liver CAD Computer-assisted detection software has moved beyond its initial applications in mammography imaging and is becoming an essential tool in the diagnosis and management of various types of cancer. At RSNA, vendors are showing systems for film and digital mammography, but the real news extends into other applications. There are new systems for chest and abdominal CT images that not only facilitate lesion detection, but also support workflow by automatically generating measurements of lung and liver lesions. RSNA-goers also can check out a prostate MRI CAD application. Similar to breast MRI CAD, the system helps users efficiently sort through the volume of MRI data to more efficiently diagnose prostate disease.

EDDA Technology (Booth 6534) is introducing the IQQA Enterprise Engine technology and highlighting the IQQA-Chest and IQQA-Liver.

The EDDA universal enterprise solution enables fast delivery and easy access of 2D/3D/4D advanced clinical applications on existing PACS workstations in any hospital PACS environment without code-level integration. The IQQA Enterprise Engine is available with IQQA-Chest for digital x-ray lung nodule CAD and IQQA-Liver for contrast MDCT of liver. The IQQA Enterprise Engine also can accommodate third-party imaging applications.

IQQA-Chest offers real-time, interactive diagnostic analysis of digital chest x-rays using a comprehensive set of tools to support physicians in the identification, confirmation and quantification of lung nodules. The system is powered by intelligent tools with real-time interaction to seamlessly integrate advanced diagnostic analysis technologies into physicians’ softcopy reading process for improved workflow and clinical decision-making. Published clinical studies suggest IQQA-Chest may help physicians identify small lesions and reduce inter-observer variation, according to the company. The immediacy provided by IQQA-Chest Enterprise allows for expanded use of chest CAD tools on a routine basis with the prospect of enhancing diagnostic quality on a broad scale.

IQQA-Liver Enterprise addresses the clinical challenge faced by physicians in efficiently dealing with tremendous data volume from contrast MDCT images of liver. Combining advanced image analysis algorithms and visualization tools, the software supports physicians to quickly and effectively distill critical diagnostic information. It performs automatic anatomy-based phase registration to allow simultaneous visualization and cross-referencing of lesion location and characteristics across different phases. IQQA-Liver Enterprise provides 3D segmentation and measurement tools for visualization and analysis of liver, liver lesions and vascular structures. This volumetric analysis provides physicians with a visualization aid and offers quantification tools to support clinical decision-making and patient care management.

Health Imaging & IT

|

November 1, 2007

|

Features

By Beth Walsh

Siemens’ syngo lung CAD offers capabilities for the detection of solid pulmonary nodules in thoracic CT studies as well as CAD workflow enhancements. Progressive clinicians are working with vendors to fine-tune CAD applications for lung imaging. Even as the tool can help radiologists detect more lung nodules, it’s only one item in a complete imaging toolset. But there’s a Catch-22: More radiologists need to use it to help prove its value, but ease of use has to improve to encourage more radiologists to use it. Lung CAD is “not a shot in the dark or a flash in the pan,” says David Naidich, MD, professor of radiology and medicine at the New York University School of Medicine & Hospitals Center in New York City. He uses syngo Lung CAD from Siemens Medical Solutions. Lung CAD has been making “very steady progress,” he says. Overall, lung CAD can aid imaging, decrease false negative findings, offers high sensitivity and has brought a 26 percent reduction in missed actionable nodules. “As the technology got better and better in CT, generating huge datasets, the concept that computers would be an additional means of interpretation became very attractive,” Naidich says. That has turned out to be a very complex set of problems for the computer to solve. Naidich doesn’t see CAD as an independent, stand-alone tool, even though it is designed to be just that. CAD isn’t used to detect nodules—which can determine whether a patient requires surgery—but also to characterize, conduct volumetric assessment, and look at contour and density to match scans later to see whether nodules have changed. Coupling CT and CAD allows for more accurate judgment in lung cancer cases, he says. To facilitate a smooth workflow, study data are streamed to Siemens Leonardo workstations. But, Naidich hopes to soon see CAD integrated into PACS configurations. “When you work on two separate systems, you have to go back and forth. It would be easier if the tools were available right from the get-go.” That ease of use would translate, Naidich says, to physicians using CAD more often and more appreciation of its value. “Until [physicians] really are using CAD, they don’t fully sense that it’s a relatively simple idea. The information you’re getting is not onerous. As long as the device doesn’t overload you, it is truly positioned to only show you things you want to see for reassurance.” Edwin van Beek, MD, PhD, radiologist at the University of Iowa Hospitals and Clinics in Iowa City, has been working with EDDA Technologies to boost the user friendliness of its IQQA Chest Enterprise software—requiring fewer clicks and offering more automation. The facility conducts research on lung nodules, so the partnership was a good fit. Since implementing IQQA Chest Enterprise from EDDA Technologies 18 months ago, the software is used for annual follow-up on all lung cancer patients. The teaching facility is fortunate in that its residents already double-read all chest x-rays. A review found that of 214 cases, CAD was the only thing that caught a finding in 19 cases. Of those 19 cases, 16 were true positives and three were false positives.  Those are very good results considering that it takes about 20 seconds to run a chest x-ray through CAD. A review of residents’ usage has shown that CAD helped them pick up 20 percent more nodules; for senior radiologists, that percentage is closer to 5 percent.

Skeptical interest

---

During a talk van Beek gave in June, he noticed a lot of skepticism but, at the same time, more interest in CAD than in recent years. Growth in the use of CAD depends on reimbursement, he says. Currently, there is a tracking code for CAD but “if there’s no reimbursement, people are not going to make the investment.” But, he feels that knowing that he’s done everything he can gives him peace of mind. The issue of missed or delayed diagnosis weighs on radiologists, however. “I have no problems sleeping at night, and I think a lot of people see it in a fairly similar way.”

Freiburg University Hospital in Hamburg, Germany, is one of the largest academic teaching hospitals in Europe with 1,600 beds and 1,150 physicians. The department of radiology employs 35 radiologists and 65 radiologic technologists, and an MR research section staffs 50 physicists. The team performs about 500 exams a day.

The facility implemented X-ray Lung Nodule Analysis (xLNA)—EDDA’s IQQA Chest Enterprise as marketed by Philips Medical Systems—in May, says Elmar Kotter, MD, senior radiologist. Although research has established CAD’s value with lung CT, its value with chest x-rays is still under evaluation, he says. Kotter has studied results from the use of xLNA and found encouraging results that he submitted for publication in Investigative Radiology.

CAD needs to be very fast and integrated into radiologists’ daily workflow, Kotter points out. He has found that xLNA is simple to integrate with PACS and is easy to learn.

Patricia Shapiro, MD, of Southcoast Medical Imaging, Savannah, Ga., has been using lung CAD from Riverain for about six months. After going all-digital years ago and implementing CAD for mammography almost two years ago, implementing lung CAD was pretty seamless, she says.

The facility implemented lung CAD because, as a multispecialty group, primary-care physicians read their own chest x-rays. “We were interested in doing this as a way to provide an additional tool to primary-care doctors.” While it has proved to be very helpful for primary-care providers, lung CAD hasn’t made as big an impact with radiologists yet, she says. “As lung CAD algorithms improve with time, it will make more difference to radiologists.” Meanwhile, CAD has value right now in her view if it encourages primary-care physicians to take a second and third look at chest x-rays.

In the future

---

Debate continues about whether CAD is a valid tool, Naidich says, and clinical evaluation has necessitated a large-scale, randomized, multi-facility study. “If the answer is that lung cancer screening is an important clinical tool in its own right, that would have tremendous impact on whether CAD to detect lung nodules would be something people want.” Study results are expected some time in 2008.

EDDA Technology, Inc.
The 93th Scientific Assembly & Annual Meeting of the Radiological Society of North America

MEETING DATES : Nov. 25 – Nov. 30, 2007
BOOTH NUMBER : North Building – Hall B6534

For more information: http://rsna2007.rsna.org/rsna2007/V2007/exhibitor_list/displayEx.cvn?exbID=1089

Princeton Junction, NJ, September 3, 2007

In this year’s “Minnies” nominations from Aunt Minnie, IQQA®-Liver Enterprise has entered the list of semi-finalists for the category of “Best New Radiology Software”.

The “Minnies” are Aunt Minnie’s equivalent of the Academy Awards in radiology.

For more information about this news, please visit:
http://www.auntminnie.com/index.asp?Sec=nws&Sub=rad&Pag=dis&ItemId=77320&wf=2047&d=1

Enabling Advanced 4D Clinical Application to Run Concurrently on Existing PACS Workstations

Princeton Junction, NJ, June 4, 2007

EDDA Technology today announced that it is introducing IQQA®-Liver Enterprise for contrast Multi-Detector CT (MDCT) abdominal imaging at the upcoming Annual Meeting of the Society for Imaging Informatics in Medicine (SIIM). The enterprise software solution enables the advanced 4D imaging application, which supports physicians’ real-time evaluation of liver and hepatic lesions, to run concurrently on hospital’s existing PACS workstations.

IQQA®-Liver addresses the clinical challenge faced by physicians in efficiently dealing with tremendous data volume from contrast MDCT images of liver. Combining advanced image analysis algorithms and powerful visualization tools, the software supports physicians to quickly and effectively distill critical diagnostic information from data volume of extraordinary size. It performs automatic anatomic phase registration to allow simultaneous visualization and easy cross-referencing of lesion location and characteristics across the different phases. IQQA®-Liver further provides 3D segmentation and measurement tools for the visualization and analysis of liver lesions, hepatic vascular structures, as well as liver lobes. This volumetric analysis not only provides physicians with a powerful visualization aid, but also offers quantification tools to support their clinical decision making and patient care management.

IQQA®-Liver Enterprise is powered with the same enabling engine technology behind
IQQA®-Chest Enterprise for digital radiography which the company introduced at RSNA 2006. The IQQA® Enterprise Engine (IQQA®-EE) aims to redefine how advanced clinical application can be accessed by radiologists and managed by radiology IT. Radiologists can now enjoy immediate access to the full real-time 3D/4D functionality of advanced clinical applications at existing PACS viewing stations. In addition, since the solution does not require code level integration with existing hospital PACS environment, application installation is completed quickly by simply setting up network communication. Possible additional maintenance resources of having to change with periodic PACS software upgrade are also saved.

“EDDA is committed to delivering new generation of diagnostic decision support solutions, which not only include advanced clinical applications to improve early detection, early diagnosis and precise treatment of lethal diseases, but also very importantly include innovations for ease of access of such applications”, says Dr. Jian-Zhong Qian, President and CEO of EDDA Technology. “From the success of development of IQQA®-Chest Enterprise to IQQA®-Liver Enterprise, IQQA®-EE demonstrates a new economic way to integrate 2D/3D/4D applications with virtually any existing hospital PACS systems without code level integration. Advanced imaging applications in this way can readily run concurrently on hospital’s existing PACS viewing stations with minimum installation and maintenance effort. Considering the trend of numerous advanced 3D/4D applications that already exist and many more that are emerging, the impact of such accessibility enabling technology will be significant.”

Liver disease is among the 10 major causes of death in the US, according to the American Liver Foundation. There are 25,000,000 Americans afflicted by liver disease. Primary liver cancer, with approximately 1,000,000 cases reported every year in the world, is one of the most common malignancies. Liver metastasis tumors also occur frequently, as any primary cancer location can deposit metastases in the liver. As the liver is generally the first site of metastatic spread, aggressive surgical intervention at an early stage of metastasis results in a reported 25-40% five-year survival rate.

The IQQA®-Liver software has been in clinical use in several luminary Chinese hospitals for liver cancer detection, diagnosis and treatment planning purposes, including Eastern Hepatobiliary Surgery Hospital in Shanghai, Peking Union Medical College Hospital in Beijing, Shanghai Ruijin Hospital, and Beijing Youyi Hospital.

The IQQA® Enterprise Engine has been successfully integrated to run in numerous PACS environments including AGFA, GE, Kodak, McKesson, Philips and etc.

EDDA Technology will be exhibiting the IQQA® Family of Products in Booth #710 at the Annual Meeting of the Society for Imaging Informatics in Medicine (SIIM), Providence, RI, June 7 – June 9, 2007.

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

Editor’s Note:
EDDA Technology will be exhibiting in Booth # 9318, and Shimadzu Corporation in Booth #5000, of McCormick Place in Chicago at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 29 – Dec. 3, 2009.

EDDA Technology, Inc.

Attend the annual Society for Imaging Informatics in Medicine meeting (formerly SCAR).

MEETING DATES : June 7 – 10, 2007
BOOTH NUMBER: 710
LOCATION: Rhode Island Convention Center, Providence, RI

For more information: http://www.siimweb.org/

EDDA Technology, Inc.

Attend the 25th Annual Meeting and Post Graduate Course of the Society of Thoracic Radiology. We look forward to seeing you there.

MEETING DATES : March 25 – 29, 2007
LOCATION: Red Rock Casino Resort in Las Vegas, NV

For more information: http://www.thoracicrad.org

Princeton Junction, NJ, November 17, 2006

EDDA Technology today announced the commercial release of IQQA®-Chest software V2.0 featuring enterprise CAD solution for digital X-ray. IQQA®-Chest is the only FDA cleared system to offer real-time interactive diagnostic analysis of digital chest X-rays using a comprehensive set of tools to support radiologists in their identification, confirmation and quantification of lung nodules.

Powered with the same computer-assisted detection support software of the debut software V1.0, IQQA®-Chest Enterprise aims to redefine how advanced clinical applications can and should be accessed by radiologists.Up to now, radiologists have simply had to accept that the use of advanced imaging software meant they would have to operate at dedicated workstations detached from their primary PACS review stations.Although static image results could often be sent from these stand-alone workstations back to a PACS for review, it was still not possible to enjoy access to the full functionality of these advanced applications at the PACS viewing station.

Responding to this clinical challenge, EDDA has developed a unique enabling solution capable of instantly deploying the full functionality of the IQQA®-Chest application on existing PACS review consoles without additional requirement or setup effort on the workstations.

According to Dr. Edwin van Beek, Professor of Radiology, University of Iowa Hospital and Clinics, the need for this level of performance is particularly critical with chest radiography, the most frequently performed imaging study. University of Iowa Hospital and Clinics, a commercial site of EDDA’s, has recently been upgraded to IQQA®-Chest Enterprise.

“With the number of chest X-rays we read on a daily basis, tomaximize the benefit from a CAD application will be highly dependent upon the accessibility we have to the full application at our PACS review stations,” added Dr. van Beek. “EDDA has cleared this hurdle with IQQA®-Chest Enterprise.The immediacy we now enjoy with this tool allows us to expand our use of the application at the University of Iowa with the prospect of further enhancing our overall detection rate.”

Dr. van Beek and his colleagues will report on a clinical study conducted at the University of Iowa in which the software was used in their daily practice since January 2006.The study suggests that the software could help residents detect more small lung nodules.The results have been accepted for presentation at the upcoming RSNA 2006 meeting.

“EDDA’s vision of seamlessly integrating our advanced detection analysis technology into the radiologist’s softcopy reading environment to improve workflow and support clinical decision-making is now being realized with IQQA®-Chest Enterprise,” said Jianzhong Qian, President and CEO of EDDA Technology, “We are pleased to provide an innovative solution that can significantly enhance the broad access of our advanced CAD application in physicians’ daily clinical practice.”

EDDA Technology will feature IQQA®-Chest Enterprise at the upcoming 92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA).RSNA 2006 will also provide the occasion for EDDA to showcase another advanced imaging application, IQQA®-Liver.Using data from a contrasted multiphase CT liver study, IQQA®-Liver provides radiologists with comprehensive tools to review all acquired phases simultaneously with automatic anatomic phase registration.It also provides segmentation and measurement tools for visualizing and analyzing liver lesions and vascular structures to support liver disease diagnosis and preoperative assessment and planning.IQQA®-Liver has clearance from the U.S. Food and Drug Administration (FDA), and Chinese State Food and Drug Administration (SFDA).

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA’s goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com

Editor’s Note:
EDDA Technology exhibit their IQQA® Family of Products in Booth # 3271 in the South Hall of McCormick Place at the 92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 26 – Dec. 1, 2006.

Princeton Junction, NJ, November 16, 2006

EDDA Technology today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market its IQQA®-Liver software, an image analysis system that provides diagnostic decision support for physicians’ evaluation of hepatic lesions using multiphase Multi-Detector CT (MDCT).

IQQA®-Liver is the first diagnostic analysis system that provides real-time decision support for managing four dimensional patient liver image data (3 spatial dimensions, plus time). With the recent advances in MDCT and dynamic imaging, early detection and treatment planning of liver diseases has been significantly enhanced.However, with these advances comes the challenge of efficiently dealing with a tremendous increase in image data. With a typical multiphase liver study generating several hundred CT images, there has never been a more urgent need for radiologists to have access to tools that can support them in making more efficient and effective diagnoses.

Combining advanced image analysis algorithms and powerful visualization tools, IQQA®-Liver supports clinical workflow for physicians to quickly and effectively distill critical diagnostic information from image data sets of extraordinary size. The software performs automatic, anatomic phase registration to allow simultaneous visualization and easy cross-referencing of lesion location and features across the different phases.

IQQA®-Liver further provides segmentation and measurement tools for the visualization and analysis of liver lesions, hepatic vascular structures, as well as liver lobes. This volumetric analysis not only provides physicians with a powerful visualization aid, but also offers quantification tools to support their clinical decision making and patient care management.

“EDDA is committed to innovation, and to improving early detection, early diagnosis and precise treatment of lethal diseases through development of the most advanced computer technologies”, says Dr. Jian-Zhong Qian, President and CEO of EDDA Technology. “Following EDDA’s debut product IQQA®-Chest software for early lung lesion detection, IQQA®-Liver is another important step forward in this direction. We will continue our efforts to provide our customers with the new generation of diagnostic decision supporting solutions”.

Liver disease is among the 10 major causes of death in the US, according to the American Liver Foundation.There are 25,000,000 Americans afflicted by liver disease. Primary liver cancer, an extreme type of malignancy that starts in the liver, is one of the most common malignancies in the world, with approximately 1,000,000 cases reported every year. This ranges from 16,000 new cases in the US to 500,000 in China. Liver metastasis tumors also occur frequently, as any primary cancer location can deposit metastases in the liver. As the liver is generally the first site of metastatic spread, aggressive surgical intervention at an early stage of metastasis results in a reported 25-40% five-year survival rate.

The IQQA®-Liver software has also been approved by the Chinese State Food and Drug Administration for marketing and production. It has been in clinical use in several luminary Chinese hospitals for liver cancer detection, diagnosis and treatment planning purposes, including Eastern Hepatobiliary Surgery Hospital in Shanghai, and Peking Union Medical College Hospital in Beijing.

EDDA Technology will feature IQQA®-Liver at the upcoming 92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA). RSNA 2006 will also provide the occasion for EDDA to showcase IQQA®-Chest Enterprise: IQQA®-Chest supports physicians in the identification, evaluation and documentation of lung lesions from digital chest radiographic images. The new Enterprise version addresses the accessibility challenge for advanced clinical applications and provides a unique enabling solution capable of instantly deploying the full functionality of the IQQA®-Chest application on existing PACS review consoles without additional requirement or setup effort on the PACS workstations. IQQA®-Chest carries the CE mark, and has clearance from the U.S. FDA, and Chinese SFDA.

About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases and enhance precision in diagnosis. EDDA’s goal is to deliver advanced information analysis technologies that improve clinical workflow and accuracy with broad accessibility. A privately held Delaware corporation, EDDA is headquartered in Princeton Junction, New Jersey, and has a regional office in Shanghai, China. In April 2006, EDDA entered into a strategic partnership with Philips Medical Systems to provide advanced digital radiography solutions to assist in the detection of lung lesions. IQQA is a registered trademark of EDDA Technology. For further information, please log on to www.edda-tech.com, or contact info@edda-tech.com or call 609-936-8282.

Editor’s Note:
EDDA Technology exhibit their IQQA® Family of Products in Booth # 3271 in the South Hall of McCormick Place at the 92nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 26 – Dec. 1, 2006.